Cargando…

Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases

Whether the expression status of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2) receptor and Ki-67 show concordance between the primary tumors and the synchronous axillary lymph node (ALN) metastases has been discussed in numerous studies. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Xi, Xun, Huang, Xing-Wei, Yuan, Huo-Zhong, He, Chun, Ni, Jun, Yang, Fu-Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520755/
https://www.ncbi.nlm.nih.gov/pubmed/33014152
http://dx.doi.org/10.3892/ol.2020.12136
_version_ 1783587839256035328
author Xi, Xun
Huang, Xing-Wei
Yuan, Huo-Zhong
He, Chun
Ni, Jun
Yang, Fu-Lan
author_facet Xi, Xun
Huang, Xing-Wei
Yuan, Huo-Zhong
He, Chun
Ni, Jun
Yang, Fu-Lan
author_sort Xi, Xun
collection PubMed
description Whether the expression status of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2) receptor and Ki-67 show concordance between the primary tumors and the synchronous axillary lymph node (ALN) metastases has been discussed in numerous studies. However, to date, the results of these studies remain controversial. Therefore, the present study aimed to investigate whether the expression of ER, PR, HER-2 and Ki-67 was in concordance between the primary tumors and synchronous ALN metastases in patients with operable breast cancer (BC). A total of 60 tissue samples were collected from patients with primary operable BC diagnosed with primary tumors and synchronous ALN metastases. The expression levels of the four biomarkers, ER, PR, HER-2 and Ki-67, were assessed in primary lesions and synchronous ALN metastases samples using immunohistochemistry. The cut-off values were set to 10% for ER and PR, while the labeling index of Ki-67 was set to 14%. The immunostaining intensity of ER and PR was scored as negative (−), 1+, 2+ and 3+. The criteria for HER-2 testing in BC were implemented according to the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) guidelines. The concordance rates for ER, PR and HER-2 were 96.7 (58/60), 96.7 (58/60) and 90% (54/60), respectively. In addition, the kappa values of consistency in the primary lesions and the synchronous ALN metastases were 0.773 for ER, 0.654 for PR and 0.785 for HER-2. Furthermore, the P-values of ER, PR and Ki-67 numerical variables between the two groups were 0.393, 0.400 and 0.331, respectively, as demonstrated using a non-parametric Wilcoxon signed rank test. The findings of the present study demonstrated a high degree of concordance between the expression of ER, PR, HER-2 and Ki-67 in the primary tumors and that in the synchronous ALN metastases, suggesting that the BC primary tumor biomarkers may be used for the prognosis of synchronous ALN metastases in patients with operable BC.
format Online
Article
Text
id pubmed-7520755
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-75207552020-10-01 Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases Xi, Xun Huang, Xing-Wei Yuan, Huo-Zhong He, Chun Ni, Jun Yang, Fu-Lan Oncol Lett Articles Whether the expression status of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2) receptor and Ki-67 show concordance between the primary tumors and the synchronous axillary lymph node (ALN) metastases has been discussed in numerous studies. However, to date, the results of these studies remain controversial. Therefore, the present study aimed to investigate whether the expression of ER, PR, HER-2 and Ki-67 was in concordance between the primary tumors and synchronous ALN metastases in patients with operable breast cancer (BC). A total of 60 tissue samples were collected from patients with primary operable BC diagnosed with primary tumors and synchronous ALN metastases. The expression levels of the four biomarkers, ER, PR, HER-2 and Ki-67, were assessed in primary lesions and synchronous ALN metastases samples using immunohistochemistry. The cut-off values were set to 10% for ER and PR, while the labeling index of Ki-67 was set to 14%. The immunostaining intensity of ER and PR was scored as negative (−), 1+, 2+ and 3+. The criteria for HER-2 testing in BC were implemented according to the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) guidelines. The concordance rates for ER, PR and HER-2 were 96.7 (58/60), 96.7 (58/60) and 90% (54/60), respectively. In addition, the kappa values of consistency in the primary lesions and the synchronous ALN metastases were 0.773 for ER, 0.654 for PR and 0.785 for HER-2. Furthermore, the P-values of ER, PR and Ki-67 numerical variables between the two groups were 0.393, 0.400 and 0.331, respectively, as demonstrated using a non-parametric Wilcoxon signed rank test. The findings of the present study demonstrated a high degree of concordance between the expression of ER, PR, HER-2 and Ki-67 in the primary tumors and that in the synchronous ALN metastases, suggesting that the BC primary tumor biomarkers may be used for the prognosis of synchronous ALN metastases in patients with operable BC. D.A. Spandidos 2020-11 2020-09-21 /pmc/articles/PMC7520755/ /pubmed/33014152 http://dx.doi.org/10.3892/ol.2020.12136 Text en Copyright: © Xi et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Xi, Xun
Huang, Xing-Wei
Yuan, Huo-Zhong
He, Chun
Ni, Jun
Yang, Fu-Lan
Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases
title Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases
title_full Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases
title_fullStr Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases
title_full_unstemmed Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases
title_short Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases
title_sort biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520755/
https://www.ncbi.nlm.nih.gov/pubmed/33014152
http://dx.doi.org/10.3892/ol.2020.12136
work_keys_str_mv AT xixun biomarkerheterogeneitybetweenprimarybreastcancerandsynchronousaxillarylymphnodemetastases
AT huangxingwei biomarkerheterogeneitybetweenprimarybreastcancerandsynchronousaxillarylymphnodemetastases
AT yuanhuozhong biomarkerheterogeneitybetweenprimarybreastcancerandsynchronousaxillarylymphnodemetastases
AT hechun biomarkerheterogeneitybetweenprimarybreastcancerandsynchronousaxillarylymphnodemetastases
AT nijun biomarkerheterogeneitybetweenprimarybreastcancerandsynchronousaxillarylymphnodemetastases
AT yangfulan biomarkerheterogeneitybetweenprimarybreastcancerandsynchronousaxillarylymphnodemetastases